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Available online 18 October 2010While the evidence for benefits from CS might arguably be
tenuous, the suggestion of harm from CS is an over-
statement of the available data. Whether the conception of
the systemic granulomatous response as discussed in the
latter half of Dr. Reich’s paper is correct or not is unclear
right now. There are data available to support alternative
hypotheses, and currently this line of reasoning is purely
speculative until proven experimentally.
Thecontention thatCScausemortality ishighly suspect for
two reasons: the correlation analysis comparing TCS to PBS is
irretrievably flawed, and close inspection of the referenced
studies does not support the conclusions reached. Major
pitfalls inDr.Reich’s analysis include substantial indiscernible
selection bias inherent in comparisons of TCS to PBS, inability
to directly relate use of corticosteroids to the outcome
(i.e., death), use of chest radiography alone to control for
disease severity, lack of accounting for extrapulmonary
disease, and racial/ethnic disparities between studies. A
review of the five city series that contributes the largest
proportion of patients to Dr. Reich’s analysis confirms the
fallacy of this approach: the three centers (Paris, Los Angeles
and Tokyo) using CS in 2/3 of their patients exhibited lowerDOI of original article: 10.1016/j.rmed.2010.07.002.
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doi:10.1016/j.rmed.2010.07.003attributable mortality (0.4e1.8%) than the two centers (New
York and London) that limited corticosteroid use to 1/3 of
patients (mortality 5%). Review of the TCS where higher
mortality is supposedly linked with the use of CS showed that
the authors in those clinics typically reserved the use of CS for
symptomatic patients, those with progressing disease or
extrapulmonary manifestations.1,2 These are the same indi-
cations suggested by Dr. Reich to result in lower mortality
with ostensibly more circumspect physicians in PBS.
As discussed previously, many of the controlled trials of
CS have major methodologic flaws. In spite of this, review
of the available controlled trials does not support the
contention of Dr Reich that there is a “2e4-fold excess of
adverse outcomes (including mortality) in CS recipients vs.
controls”. Many of the “adverse outcomes” are based on
extremely small differences in proportions of patients in
various CXR stages after treatment, often strikingly far
below the level of statistical significance. None of the
authors of these studies claimed that CS were actually
harmfuldmore usually they opined that CS were neither
beneficial nor harmful for changing the natural history. Not
one of the studies purports to show a difference in
mortality. Conflating all of these small numbers together is
not a recipe to draw reliable conclusions. In the more
rigorous Cochrane meta-analysis of controlled trials of CS,
the authors concluded that the CXR was on-balance
improved with CS but that the data did not demonstrate
benefit or harm for pulmonary function tests.3.
The treatment of the granulomatous response 1785I fully agree that the best indication for systemic
therapy of pulmonary sarcoidosis is progressive disease, but
we all encounter difficult patients with borderline indica-
tions. On which side of the fence should we sit? Right now,
the bulk of the best evidence favors cautious, titrated
treatment, not observation.Acknowledgement
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